Ergotamine Tartrate

  • # LGM Pharma is a Ergotamine Tartrate CAS# 379-79-3 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ergotamine Tartrate
  • CAS #: 379-79-3
  • Mode of Action:

    As part of the ergot alkaloid family, Ergotamine iwas one of the first ergot alkaloids to be isolated. The plentiful vasoconstrictor activities of Ergotamine Tartrate includes positive inhibitory effects on neurogenic inflammation. 

  • Pharmacodynamics:

    Ergotamine is an alpha adrenergic blocking agent that offers a direct stimulating effect on the blood vessels, thus producing a depression of the central vasomotor centers.

  • Metabolism:

    Ergotamine is metabolized in the liver with over 90 percent of the metabolites excreted in the bile as a 2 hour half-life.

  • Toxicity:

    Over dosage of Ergotamine Tartrate can be a concern and this has been documented. Symptoms of Ergotism, or an overdose of Ergotamine include vomiting, cyanosis, coma, convulsions and shock. While rare, caution should be taken by patients not to overdose on Ergotamine or products containing this drug. Side effects, albeit mild, reported from patients who took Ergotamine include nausea and dizziness.

  • PubChem: 8223
  • Formula: C33H35N5O5)2, C4H6O6
  • Molecular Mass: 1312.4
  • Synonyms: (5'alpha)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione
  • SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O
  • InChl: S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
  • General Reference:
    1. Headache. 2010.
    2. Young, WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache. 37 Suppl 1:S42-5, 1997.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service